重组腺病毒相关病毒作为肝癌基因治疗载体的初步研究  

The RESEARCH ON THE RECOMBINANT ADENO-ASSOCIATED VIRUS AS A VECTOR FOR THE GENE THERAPY Of LIVER CANCER

作　　者：刘自明[1] 严律南[1] 王忠[1] 林琦远[1] 

机构地区：[1]华西医科大学附属第一医院普外科,成都610041

出　　处：《中国普外基础与临床杂志》2001年第3期133-134,共2页Chinese Journal of Bases and Clinics In General Surgery

基　　金：国家自然科学基金项目(39770723)

摘　　要：目的探讨重组腺病毒相关病毒（ｒＡＡＶ）的制备以及作为肝癌基因治疗载体的可行性。方法重组报告事因加强的绿色荧光蛋白（ＥＧＦＰ）基因至质粒载体ｐＳｕｂ２０１，用双质粒共转染方法制备重组腺病毒相关病毒颗粒（ｒＡＡＶ／ＥＧＦＰ），观察其对肝癌细胞系的感染性。结果用常规的双质粒共转染方法能制备高产量的ｒＡＡＶ（１０７～１０８感染单位／１０ ｃｍ板）；当病毒感染多重性（ＭＯＩ）＝１００时，ｒＡＡＶ／ＥＧＦＰ对肝癌细胞 ＨｅｐＧ２的转染效率可达 １００％。 结论重组腺病毒相关病毒可有效地转导外源基因至肝癌细胞，其作为肝癌的基因治疗载体具有较好的研究前景。Objective To explore the feasibility of recombinant adeno-associated virus (rAAV) as a vector for the gene therapy of liver cancer. Methods The rAAV/enhance green fluorescein protein (EGFP) recombinant was prepared by the routine method of two plasmids cotransfection. Results The experiment showed that one 10cm plate could produce 107 -108. infection unit recombinant by the method of two plasmids cotransfection, and the transduction of HepG2 cell was increased with the increase of infection dosage of rAAV. About 100 multiplicity of infection (MOI) AAV vector could make all the tumor cell light. Conclusion Liver cancer cell can be efficiently transduced by rAAV, and AAV vector may be a valuable vector for the gene therapy of liver cancer.

关 键 词：重组腺病毒相关病毒 肝癌 基因治疗 载体 

分 类 号：R735.7[医药卫生—肿瘤] R730.5[医药卫生—临床医学]